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Individualised benefit–harm balance of
aspirin as primary prevention measure – a




Guidelines from different organisations regarding the use of aspirin for primary prevention vary despite being based
on similar evidence. Translating these in practice presents a further major challenge. The benefit–harm balance tool
developed by Puhan et al. (BMC Med 13:250, 2015) for aspirin can overcome some of these difficulties and is
therefore an important step towards personalised medicine. Although a good proof-of-concept, this tool has some
important limitations that presently preclude its use in practice or for further research. One of the major benefits of
aspirin that has become apparent in the last decade or so is its effect in preventing cancer and cancer-related
deaths. However, this benefit is clear and consistent in randomised as well as observational evidence only for
specific cancers. Additionally, it has long lag-time and carry-over periods. These nuances of aspirin’s effects demand
a specific and a more sophisticated model such as a time-varying model. Further refinement of this tool with
respect to these aspects is merited to make it ready for evaluation in qualitative and quantitative studies with the
goal of clinical utility.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0493-2
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Background
Public health or patient management guideline recom-
mendations are based on broad risk groups and very
often take only a few dimensions into account, i.e. one
or two major benefits and one or two major harms. It is
therefore no surprise that recommendations of different
organisations vary despite these being based on similar
evidence as they may consider different dimensions or
use different risk group categorisation. Guidelines for
the use of aspirin in primary prevention are an excellent
example of such divergent recommendations [1–5].
Further, even if there was one universal set of
recommendations, translating these recommendations in
practice would still present a major challenge not only
because the categorisation in broad risk groups is often
too crude to apply to an individual but also because an
individual’s clinical profile often has several more dimen-
sions to consider in addition to those which formed the
basis of the applicable recommendations. Furthermore,
individual preferences and perceptions often fall outside
the scope of guidelines, and yet these are a very import-
ant component of the ultimate informed decision which
must occur at an individual level. This underscores the
need to develop tools or methods to aid the in-depth
analysis of the benefit–harm balance at an individual’s
level in a way that also incorporates personal prefer-
ences. The benefit–harm balance tool for aspirin devel-
oped by Puhan et al. [6] is therefore one such valuable
step in our quest for personalised medicine.
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Aspirin’s effects are site-specific and time-varying
This benefit–harm balance tool [6] is a good proof-of-
concept but has some important limitations that need to
be highlighted. An important caveat about any model is
that it can only be as good as its underlying assumptions
– this is where the nuances of aspirin’s effects matter. A
large body of evidence [7–12] now exists which shows
that it takes approximately 3 and 5 years for aspirin’s
effect on cancer incidence and cancer-related deaths,
respectively, to become apparent. There is also a 5-year
carry-over benefit on cancer incidence and at least
10 years for cancer deaths following cessation of aspirin
use. Puhan et al. [6] used the Gail/National Cancer
Institute approach [13] for their modelling, however,
considering such long periods of lag as well as carry-
over benefit, time-varying modelling would have been
more appropriate.
Puhan et al. [6] also modelled aspirin’s effects on 12
cancers based on data from randomised controlled trials
(RCTs) reported by Algra and Rothwell [14]. Data from
RCTs are most robust for pre-specified primary
endpoints. Barring the Women’s Health Study [10], none
of the RCTs that have so far been reported had cancer
as their primary endpoint and Women’s Health Study
data were not included in the analyses by Algra and
Rothwell [14]. Despite these analyses, as well as others
by Rothwell et al. [11, 12, 15–17], being robust, they
should be considered in the context of data from obser-
vational studies [18]. After a thorough review of the evi-
dence [8], we concluded that a clear and large benefit
exists for colorectal, oesophageal and stomach cancer,
and the benefit for lung, breast and prostate cancer is
smaller and less clear. Many aspirin experts agree with a
beneficial effect on only three gastrointestinal (GI) tract
cancers due to the biological and pharmacological
plausibility of such an effect [19], as well as due to some
uncertainty regarding aspirin’s effects on lung, breast
and prostate cancer. Therefore, we provided sensitivity
analyses with aspirin’s beneficial effect being limited to
three GI cancers as well as colorectal cancer alone [8].
Recent analyses by the U.S. Preventive Services Task
Force also take into account only the beneficial effect on
colorectal cancer [20]. Therefore, assuming aspirin’s
effect on cancers other than colorectal, oesophageal,
stomach, lung, breast and prostate cancers is not
correct, even when simulations and repetitions consider
the statistical uncertainty of effect on other cancers.
The flexibility to adjust weights as per individual pref-
erence is a major strength of Puhan et al’s study [6].
However, they assigned a default weight of 1.0 for GI
bleeding, which is very misleading. Many end-users will
often go by the default weights and it is therefore im-
portant to get this right. Their default weight was based
on 3-year survival of 45.5 % in one study [21]. GI
bleeding is often an accompanying sign or sequelae of a
major illness and long-term survival is largely driven by
the original disease. Unlike myocardial infraction, stroke
or cancer, GI bleeding rarely results in a long-term
morbidity on its own. Therefore, using the same
approach of 5-year survival to derive weight for GI
bleeding is not appropriate and use of 30-day mortality
to determine default weight would have been more
appropriate. We have extensively reviewed 30-day mor-
tality in GI bleeding (any bleeding), and despite the
increasing mortality risk with age, it does not exceed
10 % even in older individuals [22]. Furthermore, these
mortality rates continue to fall with improving standards
of care [22]. Finally, although aspirin without doubt
increases the risk of GI bleeding, it has not been shown
to significantly increase the risk of fatal GI bleeding [23,
24]. In short, a default weight of 0.1 would have been
more appropriate than that of 1.0.
The authors discuss some of the limitations discussed
above, although these should not have existed in the first
place, even for a proof-of-concept study. A more thor-
ough approach in reviewing the current evidence as well
as an in-depth understanding of the nuances of aspirin’s
benefits and harms would have eliminated most of these
limitations, making this conceptually excellent tool ready
for the next steps of qualitative and quantitative research
studies to assess the clinical utility of such an approach.
Future directions and conclusions
Puhan et al. [6] have demonstrated a good proof-of-
concept and the computational feasibility of such bene-
fit–harm balance tool. Once refined, as discussed above,
this tool can then be subjected to further research,
including research in supplementary preference-eliciting
tools and presentation formats as discussed by the
authors. The clinical utility of such a refined tool will
also need to be evaluated in clinical trials. While further
research in such tools continues, two important areas
also merit simultaneous attention. This tool is based on
the incidence of cardiovascular, cancer and bleeding
events. Many individuals and their clinicians are keen to
know an intervention’s impact on saving lives. Therefore,
a similar tool based on mortality due to these diseases
should also be developed. The tool also needs to be
regularly updated as new reliable evidence becomes
available. If the clinical utility of such a tool is demon-
strated and the tool gets updated regularly, it will greatly
enhance our ability to deliver personalised medicine not
only by estimating the benefit–harm balance at an indi-
vidual level, based on a range of factors in that individ-
ual’s clinical profile, but also by taking that person’s
individual preferences into account. This would create a
vital link between public health and individualised medi-
cine, thus enabling personalised public health.
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